A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults

NCT06994897 · tracked via the Priya Life Science Belgium tracker

Sponsor

Pfizer

Phase

Phase 1

Started

2025-08-13

Last updated

2026-03-20

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

PF-07985631Placebo

PF-07985631: Experimental Pfizer compound which will be SC or IV

Placebo: Placebo which will be SC or IV

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07985631) for the possible treatment of a kidney disease called IgA nephropathy.

This study is seeking participants who

* are male or female between 18 and 45 years of age (55 for Japanese/Chinese/multiple dose participants)
* are deemed to be healthy

Participants in this study will receive PF-07985631 or placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.

PF-07985631 or placebo will be given as a small needle injection (in the abdomen, thigh or back of the arm) or as an IV infusion in the arm (given directly into a vein) at the study clinic. Most participants will receive PF-07985631 or placebo one time. Some participants may receive PF-07985631 or placebo once a month for 3 months.

The study will compare the experiences of people receiving PF-07985631 to those of the people who do not. This will help decide if PF-07985631 is safe and effective.

Participants who take PF-07985631 or placebo only 1 time will take part in this study for about 4 months. During this time, they will stay at the study clinic for 11 to 14 days and will have 8 more study visits at the study clinic.

Participants who take PF-07985631 or placebo more than once will take part in this study for about 6 months. During this time, they will stay at the study clinic for about 4 days a month 3 times and will have 10 more study visits at the study clinic.

During study clinic stays and study visits, blood samples will be done and safety reviews completed.

Eligibility

Sex

ALL

Min age

18 Years

Max age

55 Years

Healthy volunteers

Accepted

Inclusion: 1. Between 18 and 45 years of age who are overtly healthy. 2. Japanese/Chinese and multiple dose cohorts only: Adult participants 18 to 55 years of age who are overtly healthy may be eligible at the discretion of PI. 3. Japanese/Chinese cohorts only: Participants must have 4 biological Japanese/Chinese grandparents who were born in Japan/China. Exclusion: 1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). 2. Participants with a history of allergic or anaphylactic reaction with any investigative biologic agents. 3. History of infections requiring treatment within 28 days prior to Day 1 or any active infection at Day 1. 4. Active or latent infection with tuberculosis. 5. History of recurrent urinary tract infections AND/OR sinopulmonary infections AND/OR gastrointestinal infections requiring antibiotic treatment. 6. Known fever within the 7 days prior to dosing. 7. Active gastrointestinal (GI) tract ulcerations or GI bleeding. 8. Vaccination within 6 weeks prior to Day 1 dosing or planned vaccination during the study. 9. Positive urine drug test. 10. Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic). 11. Estimated glomerular filtration rate (eGFR) \<75 mL/min/1.73 m². 12. Chest X-ray showing any active disease in the chest, or pulmonary nodules \>0.5 cm in diameter that have not been previously evaluated, cavitary lesions or evidence of bronchiectasis. 13. Standard 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results. 14. Positive stool hematest at screening or admission. 15. Participants with ANY of the following abnormalities in clinical laboratory tests at screening: * Alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin (direct and total) ≥1.05 × upper limit of normal * Immunoglobulin G, Immunoglobulin M, Immunoglobulin A below the lower limit of normal (LLN) * Total white blood cell (WBC) below the LLN * Lymphocyte count below the LLN * Platelet count below the LLN * Hemoglobin below the LLN

Primary outcome measure(s)

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) — Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)
Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria — Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)
Number of Participants With Notable Electrocardiogram (ECG) Values — Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)
Number of Participants With Clinically Significant Abnormal Laboratory Parameters — Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 4.5 months)

Trial sites (1)

Facility	City	Region	Status
Pfizer Clinical Research Unit - Brussels	Brussels	Bruxelles-capitale, Région de	Recruiting

More Pfizer trials in Belgium

A Study to Learn About How Different Forms of Study Medicine Prifetrastat Are Taken Up Into the Blood in Healthy Adults Recruiting

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease Active, not recruiting

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer Active, not recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. Recruiting

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma Active, not recruiting

Other trials for the same condition

A Study to Investigate the Effect of a Meal At 6pm the Day Before the Colonoscopy on the Bowel Cleansing with Plenvu Active, not recruiting

A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) Recruiting

Impact of a Physical Activity Intervention on Cardiometabolic Health, Mental Health, and Lifestyle Factors. Starting soon

The Magnitude of Inter-limb Asymmetry and Its Assocation with Inter-limb Asymmetry in Distance Runners and Non-runners Recruiting

Measuring Nerve Activity in Small Human Intestinal Biopsies in IBS (Irritable Bowel Syndrome) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06994897 on ClinicalTrials.gov ↗ ← All trials in Belgium